Comparing short and standard antifungal treatment for children with candidemia
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial
This study is looking at whether kids with a fungal infection called candidemia can get better with just 7 days of antifungal treatment instead of the usual 14 days, to help find the best way to treat them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arkansas Children's Hospital Res Inst NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project ID | NIH-10912719 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of a shorter course of antifungal therapy compared to the standard treatment duration for children diagnosed with candidemia, a common invasive fungal infection. The study involves a randomized controlled trial where pediatric patients receiving initial treatment with an echinocandin antifungal will be monitored to see if they can be effectively treated with just 7 days of therapy instead of the usual 14 days. By focusing on children, the research aims to provide clearer guidelines for the optimal duration of antifungal treatment based on clinical improvement. Participants will be closely observed for their response to the treatment, including blood culture results and overall health.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who have been diagnosed with uncomplicated candidemia and are receiving initial echinocandin therapy.
Not a fit: Patients with complicated candidemia or those who do not respond to initial antifungal therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to shorter treatment durations for pediatric candidemia, reducing medication exposure and potential side effects for children.
How similar studies have performed: Previous studies have shown that shorter durations of antibacterial therapy are safe and effective, suggesting potential for success in this novel approach for antifungal treatment.
Where this research is happening
Little Rock, United States
- Arkansas Children's Hospital Res Inst — Little Rock, United States (Active)
Researchers
- Principal investigator: Steinbach, William J — Arkansas Children's Hospital Res Inst
- Study coordinator: Steinbach, William J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.